[1]王姝姝,张毅,齐晓伟,等.乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系[J].第三军医大学学报,2010,32(21):2336-2339.
 Wang Shushu,Zhang Yi,Qi Xiaowei,et al.Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer[J].J Third Mil Med Univ,2010,32(21):2336-2339.
点击复制

乳腺癌新辅助化疗后残留灶分型与ER、PR、HER-2的关系(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
32卷
期数:
2010年第21期
页码:
2336-2339
栏目:
论著
出版日期:
2010-11-15

文章信息/Info

Title:
Correlation of types of residual tumor with expressions of ER, PR and HER-2 after neoadjuvant chemotherapy in breast cancer
作者:
王姝姝张毅齐晓伟陈庆秋姜军
第三军医大学西南医院乳腺疾病中心
Author(s):
Wang Shushu Zhang Yi Qi Xiaowei Chen Qingqiu Jiang Jun
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
关键词:
乳腺癌新辅助化疗雌激素受体孕激素受体人表皮生长因子受体2
Keywords:
breast cancer neoadjuvant chemotherapy estrogen receptor progesterone receptor human epidermal growth factor receptor
分类号:
R730.23; R730.53
文献标志码:
A
摘要:
目的    探讨新辅助化疗后乳腺癌残留灶分型与雌激素受体、孕激素受体及人表皮生长因子受体2的关系。    方法    90例Ⅱ、Ⅲ期浸润性导管癌患者手术标本取半,制成全乳腺次连续大切片,显微镜下观察新辅助化疗后乳腺癌残留灶形态并分型;免疫组化检测乳腺癌化疗前后雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人表皮生长因子受体2(human epidermal growth factor receptor, HER-2)状态,并分析残留灶不同分型与新辅助化疗前、新辅助化疗后ER、PR、HER-2的表达水平及其变化情况的相关性。    结果    新辅助化疗后镜下残留灶可分为3型:Ⅰ型(向心性收缩的孤立性残留癌灶)、Ⅱ型(多灶性斑片状癌灶)、Ⅲ型(主残留病灶旁有卫星结节样残留),分别占61%(55/90)、33%(30/90)、6%(5/90)。残留灶不同分型与新辅助化疗前及新辅助化疗后ER、PR、HER-2表达水平无显著差异(P>0.05);残留灶不同分型与新辅助化疗后ER、PR、HER-2表达水平的变化无显著差异(P>0.05)。新辅助化疗后,ER、PR、HER-2表达水平降低,但无统计学差异(P>0.05)。    结论    ER、PR及HER-2不能评估新辅助化疗后乳腺癌残留灶形态类型,应该进一步结合MRI与全乳大切片进行研究,便于术前了解残留癌灶的基本形态。
Abstract:
Objective     To study the correlation between types of residual tumor and expressions of ER, PR and  HER-2 after neoadjuvant chemotherapy for breast cancer.     Methods    Samples were collected from 90 women with stages Ⅱ and Ⅲ invasive ductal carcinoma through mastectomy. The samples were cut into sub-serial section of total breast. The morphology of residual tumor was observed and typed under microscope after neoadjuvant chemotherapy. Expressions of ER, PR and HER-2 was detected by immunohistochemistry (IHC). Correlation between expression levels of ER, PR and HER-2 in different types of residual tumor was analyzed before and after neoadjuvant chemotherapy.     Results    The residual tumor was divided into typeⅠ(solitary residual tumor), typeⅡ(multifocal residual tumor) and type Ⅲ(main mass with smaller satellite nodules), accounting for 61% (55/90), 33% (30/90) and 6% (5/90), respectively. No significant difference was observed in expression levels of ER, PR, HER-2 before and after neoadjuvant chemotherapy (P>0.05). The expression levels of ER, PR and HER-2 were lower after neoadjuvant chemotherapy than before neoadjuvant chemotherapy.     Conclusion    ER, PR and HER-2 cannot be used to evaluate the types of residual tumor after neoadjuvant chemotherapy. MRI in combination with sub-serial section of total breast should be used to show the morphology of residual tumor before operation.

相似文献/References:

[1]朱宁生,张婧,曾晓华,等.BMP-4基因影响乳腺癌细胞增殖、凋亡和迁移能力涉及NF-κB途径[J].第三军医大学学报,2012,34(18):1910.
[2]陈显春,杨英,宋爽,等.乳腺癌患者发生化疗性静脉炎的原因分析及防治对策[J].第三军医大学学报,2007,29(21):2055.
[3]陈显春,杨英,宋爽,等.乳腺癌病友联谊会对提高乳腺癌患者生活质量的作用[J].第三军医大学学报,2007,29(20):1967.
[4]邓莉,张轩珍,王卫东,等.重组人内皮抑素联合紫杉醇+顺铂化疗方案治疗人乳腺癌祼鼠移植瘤的研究[J].第三军医大学学报,2008,30(09):783.
 DENG Li,ZHANG Xuan-zhen,WANG Wei-dong,et al.Recombinant human endostatin combined with paclitaxel-cisplatin chemotherapy in treatment of human breast cancer xenograft in nude mice[J].J Third Mil Med Univ,2008,30(21):783.
[5]黄红梅,陈显春.男性乳腺癌患者的心理分析及对策[J].第三军医大学学报,2007,29(23):2222.
[6]杨新华,姜军,范林军,等.乳腺癌腔镜内乳淋巴结清扫的初步研究[J].第三军医大学学报,2007,29(17):1719.
 YANG Xin-hua,JIANG Jun,FAN Lin-jun,et al.Thoracoscopic internal mammary nodes dissection for breast cancer[J].J Third Mil Med Univ,2007,29(21):1719.
[7]廖翠薇,邹利光,戴书华,等.动态增强磁共振成像对乳腺癌的诊断[J].第三军医大学学报,2008,30(16):1516.
 LIAO Cui-wei,ZOU Li-guang,DAI Shu-hua,et al.Diagnosis of breast cancer with dynamic contrast-enhanced magnetic resonance imaging[J].J Third Mil Med Univ,2008,30(21):1516.
[8]张涛,汤为学,蔡辉,等.不同转移潜能乳腺癌细胞亚系的建立与生物学特性的分析[J].第三军医大学学报,2008,30(18):1726.
 ZHANG Tao,TANG Wei-xue,CAI Hui,et al.Establishment of breast cancer cell sublines with different potential of metastasis and their biological characteristics[J].J Third Mil Med Univ,2008,30(21):1726.
[9]李霞,邓华瑜.格尔德霉素对乳腺癌细胞HSP、突变型p53和CDK4表达的影响[J].第三军医大学学报,2007,29(13):1320.
 LI Xia,DENG Hua-yu.Effects of geldanamycin on expression of HSP, mutant p53 and CDK4 in human breast cancer cells[J].J Third Mil Med Univ,2007,29(21):1320.
[10]凡庆东,姜军,杨新华,等.新辅助化疗对乳腺癌Survivin、p53表达影响及意义[J].第三军医大学学报,2007,29(11):1096.
 FAN Qing-dong,JIANG Jun,YANG Xin-hua,et al.Effect of neoadjuvant chemotherapy on Survivin, p53 expression in breast cancer[J].J Third Mil Med Univ,2007,29(21):1096.
[11]张毅,周艳,郭美琴,等.全乳大切片观察新辅助化疗后乳腺癌浸润性生长特征变化[J].第三军医大学学报,2007,29(21):2083.
 ZHANG Yi,ZHOU Yan,GUO Mei-qin,et al.Infiltrating characteristics of breast cancer after neoadjuvant chemotherapy: whole breast serial subsection observation[J].J Third Mil Med Univ,2007,29(21):2083.

更新日期/Last Update: 2010-11-05